RxDoctor Payments Data

Michael Lock, OD

Optometrist · West Des Moines, IANPI 1649350331

Payments from drug & device makers

What this record shows

10 manufacturers reported payments, led by Alcon at 43.2% of the total. Reporting peaked in 2023 at $1,361 and has fallen 72.4% since, to $376 in 2025. Among optometrist clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,516in general payments, 2019–2025

Across 66 payments — averaging $53.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Biotissue Holdings Inc.$1K
  • Johnson & Johnson Vision Care, Inc.$446
  • Sight Sciences, Inc.$140
  • Amgen$88
  • Tarsus Pharmaceuticals, Inc.$47
  • plus $63 from 4 others

What the payments were for

  • Travel & lodging$1,54444%
  • Food & beverage$1,97356%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,516 in reported general payments places this provider in the 95th percentile of 559 optometrist providers in Iowa.

See all optometrist providers in Iowa

Medicare billing

Part B allowed, 2024
$56,895
Medicare patients
322
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine24$18,977
XiidraLifitegrast15$10,652
Restasis MultidoseCyclosporine15$9,707
LumiganBimatoprost11$5,113
Latanoprost89$573
Prednisolone Acetate16$509
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha27$267
Doxycycline Hyclate12$133
Timolol Maleate31$118
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Lumigan$14$33,79750 claims
Bausch & Lomb Americas Inc.Xiidra$19$10,65215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 optometrist providers in Iowa.

Other optometrist in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →